Molybdenum Cofactor Deficiency – A Single-Center Experience

Year 2026, Volume: 28 Issue: 1 , 84 - 89 , 27.04.2026

Ayşen Koçyiğit , Buğse Tıraş , Ayşe Şenol Ersak , Kısmet Çıkı , Yılmaz Yıldız , Ali Dursun , Serap Sivri

https://doi.org/10.24938/kutfd.1814845

https://izlik.org/JA39JN74WS

Abstract

Objective: Molybdenum cofactor deficiency (MoCD) is a rare, severe, autosomal recessive metabolic disorder characterized by the loss of function of molybdenum-dependent enzymes. This study aimed to evaluate the clinical, biochemical, radiological, and genetic features of MoCD patients followed in our center.
Material and Methods: Medical records of 10 patients diagnosed with MoCD at the Hacettepe University Department of Pediatric Metabolism between 2009 and 2025 were retrospectively reviewed. Demographic characteristics, clinical findings, laboratory results, neuroimaging and EEG findings, and genetic analyses were assessed.
Results: Eight patients were male (n=8), and parental consanguinity was present in nine patients (n=9). Eight patients were classified as early-onset, while two were late-onset. Seizures were the most common presenting symptom in early-onset patients, whereas late-onset cases presented with post-infectious motor deficits without seizures. Laboratory evaluation revealed universally low plasma uric acid levels (0-2 mg/dL) and variable urinary sulfite levels. Neuroimaging showed cystic encephalomalacia in all patients. Neuroimaging showed cystic encephalomalacia in all patients. Genetic analysis, performed in seven patients, identified MOCS1 variants in three patients and MOCS2 variants in four patients. During follow-up, seven patients died, with ages at death ranging from 6 to 103 months. Six of the seven deceased patients belonged to the early-onset MoCD group. Three patients are still alive. The mean survival time was 73.4 months.
Conclusion: MoCD should be considered in the differential diagnosis of neonates presenting with intractable seizures and low uric acid levels, but clinicians should also be aware that clinical manifestations may appear beyond the neonatal period.

Keywords

Early-onset , late-onset , molybdenum cofactor deficiency , sulfur , uric acid

MOLİBDEN KOFAKTÖR EKSİKLİĞİ-TEK MERKEZ DENEYİMİ

https://izlik.org/JA39JN74WS

Abstract

Amaç: Molibden kofaktör eksikliği (MoKE), molibden-bağımlı enzimlerin işlev kaybı ile karakterize, nadir görülen, ağır seyirli otozomal resesif geçişli bir metabolik hastalıktır. Bu çalışmada bölümümüzde takip edilen MoKE olgularının klinik, biyokimyasal, radyolojik ve genetik özelliklerinin değerlendirilmesi amaçlanmıştır.
Gereç ve Yöntemler: Hacettepe Üniversitesi Çocuk Metabolizma Bilim Dalında 2009-2025 yılları arasında MoKE tanısı alan 10 hastanın dosyaları geriye dönük olarak incelendi.
Bulgular: Hastaların demografik özellikleri, klinik bulguları, laboratuvar sonuçları, görüntüleme ve EEG bulguları ile genetik analizleri değerlendirildi. Olguların 8’i erkekti (n=8) ve 9’unda (n=9) ebeveynler arasında akrabalık vardı. Sekiz hasta erken, iki hasta geç başlangıçlı MoKE grubundaydı. Erken başlangıçlı olgularda nöbetler en sık bulgu iken geç başlangıçlı olgular enfeksiyon sonrası gelişen motor kayıp ile başvurmuş ve nöbet izlenmemiştir. Laboratuvar incelemelerinde tüm hastalarda ürik asit düzeyi düşük olup 0-2 mg/dL aralığındaydı ve idrar sülfit düzeyleri değişkendi. Kraniyal görüntülemede tüm olgularda kistik ensefalomalazi saptanmıştır. Genetik analiz yapılan 7 hastadan 3’ünde MOCS1, 4’ünde MOCS2 varyantı gösterilmiştir. İzlemde 7 hasta kaybedilmiş olup kaybedilme yaşları 6-103 ay arasındaydı. Kaybedilen 7 hastanın 6’sı erken başlangıçlı MoKE grubundaydı. 3 hasta yaşamını sürdürmektedir. Ortalama yaşam süresi 73,4 aydır.
Sonuç: MoKE yenidoğan döneminde başlayan inatçı nöbet ve düşük ürik asit düzeyi varlığında ayırıcı tanıda ön planda düşünülmelidir. Yenidoğan dönemi dışında da klinik bulguların görülebileceği unutulmamalıdır.

Keywords

Erken başlangıç , geç başlangıç , molibden kofaktör eksikliği , sülfür , ürik asit

References

• Misko A, Mahtani K, Abbott J, Schwarz G, Atwal P. Molybdenum cofactor deficiency. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews((R)). 1993.
• Schwahn BC, van Spronsen F, Misko A, et al. Consensus guidelines for the diagnosis and management of isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies. J Inherit Metab Dis. 2024;47(4):598-623.
• Spiegel R, Schwahn BC, Squires L, Confer N. Molybdenum cofactor deficiency: A natural history. J Inherit Metab Dis. 2022;45(3):456-469.
• Kikuchi K, Hamano S, Mochizuki H, Ichida K, Ida H. Molybdenum cofactor deficiency mimics cerebral palsy: Differentiating factors for diagnosis. Pediatr Neurol. 2012;47(2):147-149.
• Topcu M, Coskun T, Haliloglu G, Saatci I. Molybdenum cofactor deficiency: Report of three cases presenting as hypoxic-ischemic encephalopathy. J Child Neurol. 2001;16(4):264-270.
• Scelsa B, Gasperini S, Righini A, Iascone M, Brazzoduro VG, Veggiotti P. Mild phenotype in molybdenum cofactor deficiency: A new patient and review of the literature. Mol Genet Genomic Med. 2019;7(6):e657.
• Fund E, Mandel H, Zehavi Y, Spiegel R. Molybdenum cofactor deficiency: Type A disease in Northern Israel. Isr Med Assoc J. 2025;27(3):142-146.
• Vijayakumar K, Gunny R, Grunewald S, et al. Clinical neuroimaging features and outcome in molybdenum cofactor deficiency. Pediatr Neurol. 2011;45(4):246-252.
• Reiss J, Hahnewald R. Molybdenum cofactor deficiency: Mutations in GPHN, MOCS1, and MOCS2. Hum Mutat. 2011;32(1):10-18.
• Abe Y, Aihara Y, Endo W, et al. The effect of dietary protein restriction in a case of molybdenum cofactor deficiency with MOCS1 mutation. Mol Genet Metab Rep. 2021;26:100716.
• Schwarz G, Basel DG, Schwahn BC, et al. Increased survival in patients with molybdenum cofactor deficiency type A treated with cyclic pyranopterin monophosphate. J Inherit Metab Dis. 2025;48(2):e70000.
• Duran M, Beemer FA, van de Heiden C, et al. Combined deficiency of xanthine oxidase and sulphite oxidase: A defect of molybdenum metabolism or transport? J Inherit Metab Dis. 1978;1(4):175-178.
• Kinsinger M, Ivanisevic J, Mithal DS. Novel pathogenic variant in a mild case of type B molybdenum cofactor deficiency: Case report and literature review. BMC Med Genomics. 2024;17(1):292.
• Almudhry M, Prasad AN, Rupar CA, et al. A milder form of molybdenum cofactor deficiency type A presenting as Leigh's syndrome-like phenotype highlighting the secondary mitochondrial dysfunction: A case report. Front Neurol. 2023;14:1214137.
• Alkufri F, Harrower T, Rahman Y, et al. Molybdenum cofactor deficiency presenting with a parkinsonism-dystonia syndrome. Mov Disord. 2013;28(3):399-401.
• Hughes EF, Fairbanks L, Simmonds HA, Robinson RO. Molybdenum cofactor deficiency-phenotypic variability in a family with a late-onset variant. Dev Med Child Neurol. 1998;40(1):57-61.
• Lee HF, Hsu CC, Chi CS, Tsai CR. Genotype-phenotype dissociation in two Taiwanese children with molybdenum cofactor deficiency caused by MOCS2 mutation. Neuropediatrics. 2022;53(3):200-203.
• Selvanathan A, Kankananarachchi I, Bansal S, et al. Early postnatal hepatocyte transplantation in a child with molybdenum cofactor deficiency type B. Mol Genet Metab. 2025;145(1):109079.